Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.26 USD
Change Today +0.002 / 0.77%
Volume 334.2K
INSV On Other Exchanges
Symbol
Exchange
OTC US
As of 3:40 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

insite vision inc (INSV) Snapshot

Open
$0.26
Previous Close
$0.26
Day High
$0.26
Day Low
$0.26
52 Week High
09/10/14 - $0.36
52 Week Low
04/14/15 - $0.12
Market Cap
34.4M
Average Volume 10 Days
667.0K
EPS TTM
$-0.10
Shares Outstanding
132.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSITE VISION INC (INSV)

insite vision inc (INSV) Related Bloomberg News

View More Bloomberg News

insite vision inc (INSV) Related Businessweek News

No Related Businessweek News Found

insite vision inc (INSV) Details

InSite Vision Incorporated, an ophthalmic product development company, engages in developing ophthalmic pharmaceutical products to address unmet eye care needs in the United States. The company develops its products based on its proprietary DuraSite drug delivery technology. It offers AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. The products under development include BromSite, which has completed Phase III clinical trials for the treatment of post-operative inflammation, as well as the prevention of post-operative eye pain; DexaSite, which has completed Phase III clinical trials for the treatment of ocular inflammation; and AzaSite Plus, a fixed combination of azithromycin and dexamethasone that is in Phase III clinical trials for the treatment of ocular inflammation and infection. It is also developing DuraSite 2, a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing ophthalmic therapeutics; and ISV-101, a DuraSite formulation with low concentration of bromfenac that is used for the treatment of dry eye diseases. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.

29 Employees
Last Reported Date: 02/18/15
Founded in 1986

insite vision inc (INSV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $392.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $274.8K
Vice President of Operations and Quality
Total Annual Compensation: $243.4K
Chief Medical Officer, Vice President of Clin...
Total Annual Compensation: $357.7K
Vice President of Development and Secretary
Total Annual Compensation: $298.7K
Compensation as of Fiscal Year 2014.

insite vision inc (INSV) Key Developments

InSite Vision Incorporated Announces FDA Acceptance of NDA Filing for BromSite

InSite Vision Incorporated announced that the U.S. Food and Drug Administration (FDA), in a Day-74 letter, has accepted for review InSite's New Drug Application (NDA) for BromSite(TM) (0.075% bromfenac). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 10, 2016. InSite is seeking FDA approval for BromSite in the treatment of inflammation and prevention of ocular pain in the post-cataract surgery setting. BromSite has a long patent life extending to August 2029.

InSite Vision Incorporated Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months for the June 30, 2015

InSite Vision Incorporated reported unaudited consolidated earnings results for the second quarter and six months for the June 30, 2015. For the quarter, the company reported revenues of $392,000 against $6,349,000 a year ago. Loss from operations was $5,890,000 against $2,256,000 a year ago. Net loss was $6,637,000 or $0.05 per share basic and diluted against net profit of $37,149,000 or $0.28 per share basic and diluted a year ago. For the six months, the company reported revenue of $3,768,000 against $7,502,000 a year ago. Loss from operations was $6,387,000 against $1,216,000 a year ago. Net loss was $7,465,000 or $0.06 per share basic and diluted against net profit of $32,470,000 or $0.25 per share basic and diluted a year ago.

Vision Incorporated Completes NDASubmission to US FDA for BromSite

InSite Vision Incorporated announced that it has completed the submission to the US Food and Drug Administration (FDA) of the New Drug Application (NDA) of BromSite for the treatment of inflammation and prevention of pain in cataract surgery. InSite is seeking marketing approval of BromSite in the United States. In its confirmatory Phase 3 clinical trials, BromSite achieved statistically significant superiority to vehicle in alleviating ocular inflammation and the prevention of pain. In such trials, BromSite was well tolerated with no significant safety concerns or drug-related serious adverse events reported. Cataract surgery is the most frequently performed ocular surgery in the United States with more than three million procedures annually. Typically, anti-inflammatory eye drops are prescribed to reduce pain and inflammation both before and after surgery. The filing of the BromSite NDA satisfies InSite's obligation under its recently announced merger agreement with QLT Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSV:US $0.26 USD +0.002

INSV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $92.09 USD -1.89
Pfizer Inc $31.36 USD -0.86
Santen Pharmaceutical Co Ltd ¥1,804 JPY -91.00
View Industry Companies
 

Industry Analysis

INSV

Industry Average

Valuation INSV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSITE VISION INC, please visit www.insitevision.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.